NORTH BRUNSWICK, NJ – The CEO of Chromocell says the drug discovery company's newly-completed $4.2 million headquarters and laboratories aren't the only sign of growth here.

In addition to the facility expansion, which increased the firm's footprint to 15,000 square feet from nearly 6,000 square feet, Chromocell is seeking to hire immediately four employees, including three scientists who would specialize in research, CEO Christian Kopfli told BioRegion News last week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: genomic analysis of Malaysian tuberculosis strain, database of bat genomes, and more.

An editorial appearing at The Scientist bemoans the high numbers of mitochondrial genome papers and suggests a different path for mitochondrial genome research.

Researchers and drug developers are excited about the potential of CRISPR-Cas9-based therapeutics, the Wall Street Journal reports.

US lawmakers want to develop a new incarnation of the National Children's Study, ScienceInsider reports.